Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05571917 · ClinicalTrials.gov registry record · NA

Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial

A NA study of Chronic Pain and Opioid Use Disorder, sponsored by University of New Mexi.

Active
Registry status
NA
Development phase
160
Enrollment target
2
Study locations

NCT05571917: Active NA study of Chronic Pain and Opioid Use Disorder, sponsored by University of New Mexi.

NCT05571917 is a NA study of Chronic Pain and Opioid Use Disorder that is active but no longer recruiting, run by University of New Mexi. The registered enrollment target is 160 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05571917, a NA study of Chronic Pain and Opioid Use Disorder, is active but no longer recruiting, sponsored by University of New Mexi.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
2
Study locations

Study Summary

This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are currently being treated in clinics specializing in the physician management of OUD. To increase generalizability of study findings and increase internal validity of the physician management component of treatment, all participants will be stabilized on buprenorphine for OUD as part of their usual clinical care. Individuals will be randomized to either: (1) enhanced usual care or (2) the integrated ACT + MBRP treatment. The investigators hypothesize that: (1) the combination of ACT + MBRP in buprenorphine-prescribed patients with chronic pain will be more efficacious across primary and secondary outcome measures in comparison to Enhanced Usual Care and (2) examination of treatment mechanism data will indicate treatment-related changes that are consistent with the theoretical models of ACT+MBRP.

Primary Outcome

Pain interference between participants randomized to ACT+MBRP vs EUC assessed by Pain interference will be measured via Patient Reported Outcome Measurement Information System (PROMIS) Bank v1.0 Pain Interference: The National Institutes of Health (NIH) PROMIS toolkit measure for pain interference. Each item ranges from 0 (not at all) to 5 (very much interfered) and higher scores reflect more severe pain interference. This questionnaire asks about pain interference in the past 7 days (collected

Interventions

  • BEHAVIORAL Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP)
  • BEHAVIORAL Enhance Usual Care (EUC)

Study Locations (2)

Michigan

  • University of Michigan - Ann Arbor

New Mexico

  • University of New Mexico - Albuquerque

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2023-05-05
Est. Completion 2026-12-31
Phase NA
University of New Mexi

76 total trials

What the registry record for NCT05571917 still lists

NCT05571917 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (79% lower).

The record links to 2 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) is the first listed.

NCT05571917 reports a single indexed study location in Michigan, New Mexico.

Frequently Asked Questions

What is clinical trial NCT05571917 about?

NCT05571917 is a clinical study titled "Healing Opioid Misuse and Pain Through Engagement (HOPE) Trial". This study is a multisite randomized clinical trial of a treatment designed to reduce pain interference while simultaneously addressing relapse prevention among individuals who have co-occurring chronic pain and Opioid Use Disorder (OUD). This study will recruit approximately 160 individuals who are...

What is the current status of trial NCT05571917?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2023-05-05. Estimated completion is 2026-12-31.

What conditions does trial NCT05571917 study?

This clinical trial studies the following conditions: Chronic Pain, Opioid Use Disorder.

What interventions are being tested in trial NCT05571917?

The interventions under investigation include: Acceptance and Commitment Therapy + Mindfulness Based Relapse Prevention (ACT + MBRP) (BEHAVIORAL), Enhance Usual Care (EUC) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05571917?

This trial is sponsored by University of New Mexi, which has 76 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05571917 being conducted?

This trial has 2 study locations across Michigan, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05571917's enrollment target sits among peer trials

160 97th of 301 higher than 203 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05571917, the US trial registry maintained by the National Library of Medicine. NCT05571917 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.